

ASX ANNOUNCEMENT

27 April 2021

ANTERIS HITS KEY MILESTONE

Brisbane, Australia and Minneapolis, USA. Anteris Technologies Ltd (ASX: AVR; **Anteris** or the **Company**) reports reaching concept lock on critical components of its ComASUR™ Transfemoral Delivery System. Most importantly, the novel commissural alignment component which gives the physician the ability to align the commissures of the replacement valve to the native valve is now fully functional. This aspect of Transcatheter Aortic Valve Replacement (TAVR) delivery is not available with currently marketed products but is highly desired by physicians.

A series of acute animal studies demonstrated the feasibility of the DurAVR™ THV (prosthetic aortic valve) and its bespoke ComASUR™ delivery system. The studies were specifically designed to show the ComASUR™ delivery system's ability to access the arterial vasculature using minimally invasive techniques and track through the aortic arch to the aortic valve where a DurAVR™ THV was implanted.

Moreover, the studies demonstrated the deflection features of the ComASUR™ delivery system as it traversed the anatomical features as well as the ability to align the DurAVR™ THV with the native commissures of the aortic valve prior to implantation. Post-implant echocardiography and CT scan confirmed the functionality of the DurAVR™ THV with stable positioning and good hemodynamic function.

The studies are a critical part of the test plans agreed with the FDA as part of its approval process for the Company's Early Feasibility Study planned later in the year.

"This milestone is highly significant as we continue to innovate our product offerings. The commissural alignment component will give physicians the ability to deliver DurAVR™ accurately and consistently leading to better outcomes for patients. This further strengthens our three key technology pillars (ADAPT®, DurAVR™ and ComASUR™). As we advance towards our FDA EFS submission, these milestones are critical to ensure study approval. Our team continues to run studies and tests as aligned with the FDA requirements for EFS approval, Anteris Chief Executive Officer, Mr Wayne Paterson said.

ENDS

About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd is a structural heart company delivering clinically superior and durable solutions through better science and better design. Its focus is on developing next generation technologies that help healthcare professionals create life-changing outcomes for patients.

The Anteris DurAVR™ aortic replacement valve addresses the acute need in terms of superior hemodynamic profile as well as chronic needs in its ability to sustain that profile longer over the lifetime of the patient.

The proven benefits of its ADAPT® tissue technology, paired with DurAVR™'s unique 3D single-piece aortic valve design, has the potential to deliver a functional cure to aortic stenosis patients and provide a much-needed solution to the challenges facing heart surgeons today.

Anteris Technologies Ltd Registered Office:

Toowong Tower, Suite 302, Level 3, 9 Sherwood Rd, Toowong, Queensland, 4066

Customer Service

T +61 1300 550 310 | F +61 1300 972 437 | E info@anteristech.com | W anteristech.com

Brisbane • Minneapolis • Geneva • Malaga



Authorisation and Additional information

This announcement was authorised by Mr Wayne Paterson, Chief Executive Officer.

For more information:

Ms Kyahn Williamson

WE Communications

E: WE-AUAnterisTech@we-worldwide.com

P: +61 401 018 828

www.anteristech.com

Twitter: @AnterisTech

Facebook: www.facebook.com/AnterisTech